Objective: To analyze the correlation between the levels of LPS (Lipopolysaccharide) and LBP (Lipopolysaccharide-binding protein) in feces and plasma and neurological function in patients with Parkinson’s disease (PD). Methods: Thirty patients with PD (PD group) who met the inclusion and exclusion criteria and were treated at the neurology outpatient clinic/inpatient department of Heilongjiang Provincial Hospital from March 2025 to December 2025 were selected. Thirty age- and gender-matched healthy individuals who underwent health screenings during the same period were selected as the healthy control group (HC group). The levels of LPS and LBP in feces and plasma were compared between the two groups. Results: After testing, the levels of LPS and LBP in feces and plasma of the PD group were significantly higher than those of the HC group. Among PD patients, the levels of LPS in feces of patients in stages III-V were significantly higher than those in stages I-II. The levels of LPS in the plasma of patients in stages III-V were significantly higher than those in stages I-II. The levels of LBP in feces and plasma of patients in stages III-V were significantly higher than those in stages I-II. There was a positive correlation between the levels of LPS in feces and the UPDRS (Unified Parkinson’s Disease Rating Scale) scores in PD patients (r=0.68, P<0.01). There was a positive correlation between the levels of LPS in plasma and the UPDRS scores (r=0.72, P<0.01). There was a positive correlation between the levels of LBP in feces and the UPDRS scores in PD patients (r=0.65, P<0.01). There was a positive correlation between the levels of LBP in plasma and the UPDRS scores (r=0.70, P<0.01). Conclusion: The levels of LPS and LBP in feces and plasma can serve as important indicators for evaluating patients with PD, and there is a positive correlation between these levels and neurological function in PD patients.